NASDAQ:SNGX Soligenix (SNGX) Stock Price, News & Analysis $3.63 +0.10 (+2.83%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Soligenix Stock (NASDAQ:SNGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soligenix alerts:Sign Up Key Stats Today's Range$3.53▼$3.6550-Day Range$3.09▼$5.1852-Week Range$1.83▼$32.00Volume38,478 shsAverage Volume922,191 shsMarket Capitalization$3.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Read More… Publisher makes HUGE discovery (Ad)TradingPub Publisher Nate Tucci recently sat down with Chris Pulver to learn about the $100 Challenge. Chris walked him through the trade on a private Zoom call… And he was very clear… This wasn’t a “get rich quick” penny stock scheme… Or an AI stock picker that “cracked the code” of the stock market… It was just a simple, daily trade that anyone could set up at about 9:40 in the morning to target $100 a day or more (starting with just $1,000)...Sign up here to save your seat and learn more Soligenix Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks9th Percentile Overall ScoreSNGX MarketRank™: Soligenix scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Soligenix.Read more about Soligenix's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soligenix are expected to grow in the coming year, from ($5.10) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soligenix is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soligenix is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoligenix has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Soligenix's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.61% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 23.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.61% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 23.84%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News SentimentN/A News SentimentSoligenix has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Soligenix this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.36% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 3.60% of the stock of Soligenix is held by institutions.Read more about Soligenix's insider trading history. Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Stock News HeadlinesSoligenix Invited to Present at Upcoming Investor ConferencesOctober 16 at 7:30 AM | prnewswire.comHyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer ConferenceOctober 7, 2024 | prnewswire.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.October 18, 2024 | Insiders Exposed (Ad)SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development…October 3, 2024 | msn.comSoligenix (NASDAQ:SNGX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comSoligenix, Sterling Pharma Partner To Develop Production Technology For Synthetic HypericinOctober 3, 2024 | markets.businessinsider.comSoligenix Announces Partnership with Sterling Pharma SolutionsOctober 3, 2024 | prnewswire.comJoin Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024September 16, 2024 | prnewswire.comSee More Headlines SNGX Stock Analysis - Frequently Asked Questions How have SNGX shares performed this year? Soligenix's stock was trading at $12.1152 at the beginning of 2024. Since then, SNGX shares have decreased by 70.0% and is now trading at $3.63. View the best growth stocks for 2024 here. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) released its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.11) by $0.80. Soligenix had a negative net margin of 1,473.38% and a negative trailing twelve-month return on equity of 256.12%. When did Soligenix's stock split? Soligenix's stock reverse split before market open on Thursday, June 6th 2024. The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soligenix investors own include Tonix Pharmaceuticals (TNXP), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), T2 Biosystems (TTOO), iBio (IBIO) and Dynavax Technologies (DVAX). Company Calendar Last Earnings8/09/2024Today10/17/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNGX CUSIPN/A CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees20Year Founded1987Profitability EPS (Most Recent Fiscal Year)($11.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,140,000.00 Net Margins-1,473.38% Pretax Margin-1,603.77% Return on Equity-256.12% Return on Assets-72.04% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.52 Sales & Book Value Annual Sales$840,000.00 Price / Sales4.27 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book0.95Miscellaneous Outstanding Shares987,000Free Float2,216,000Market Cap$3.58 million OptionableNot Optionable Beta1.84 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:SNGX) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.